Madeleine Johnson

Editor

Phone Number

+1-212-651-5639

Email

[email protected]

Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.

Articles Authored by Madeleine Johnson

Sep 16, 2020

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

Premium

Reported as "nucleic acid amplification test-detectable" units per milliliter, the limits of detection of more than 50 commercial tests differed by 10,000-fold.

Sep 11, 2020

Ultra-Cheap, Sensitive DNA Nanoswitch Tech Developed for SARS-CoV-2 Detection

Premium

The method uses standard lab equipment and the nanoswitches can be easily reconfigured and made in large batches at a cost of about $0.01 per reaction.

Sep 11, 2020

Head-to-Head Study Suggests BD Rapid Antigen Test Sensitivity is Equivalent to Quidel's

Premium

Comparing the BD and Quidel rapid antigen tests showed they performed similarly despite sensitivity differences in initial FDA filings.

Sep 10, 2020

FDA Joins PGx Collaborative Community but Effect on Field is Unclear

Premium

The community is poised to be the primary channel for stakeholders to communicate PGx concerns with FDA, but it is unclear if all stakeholders will participate.

Sep 01, 2020

SARS-CoV-2 Testing Boosts EliTech Assay, Instrument Sales

Premium

The firm was one of the first to have a COVID-19 test receive EUA from the FDA. It is also developing a COVID-19/flu combo test for which it will seek EUA.

Aug 31, 2020

COVID-19 Accelerates Scope Fluidics' Multiplex Point-of-Care MDx Development

Premium

The Warsaw, Poland-based startup expects to submit a rapid SARS-CoV-2 molecular test for EUA and is seeking US manufacturing and distribution partners.

Aug 27, 2020

Resilience Health Curating COVID-19 Molecular Tests for Employers, Public Benefit

Premium

The New York startup is curating available data for all Emergency Use Authorized molecular diagnostic tests for the benefit of the public.

Aug 18, 2020

With New NIH Funding, PathogenDx Pivots From Cannabis Screening to Clinical Diagnostics

Premium

Funding from RADx and NIAID will enable the scale-up of multiplexed viral detection microarrays to 4 million tests per month.

Aug 17, 2020

Biodesix Turns to Digital PCR to Maintain Round-The-Clock COVID Testing

Premium

The firm is using ddPCR to support testing 3,000 samples per day with a turnaround time of approximately 24 hours

Aug 13, 2020

Many Initiatives Turning to RT-LAMP as Alternative to PCR for Rapid COVID-19 Screening Assays

Premium

screening assay NEB colorimetric reagents

Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.

Menu

Madeleine Johnson

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

Ultra-Cheap, Sensitive DNA Nanoswitch Tech Developed for SARS-CoV-2 Detection

Head-to-Head Study Suggests BD Rapid Antigen Test Sensitivity is Equivalent to Quidel's

FDA Joins PGx Collaborative Community but Effect on Field is Unclear

SARS-CoV-2 Testing Boosts EliTech Assay, Instrument Sales

COVID-19 Accelerates Scope Fluidics' Multiplex Point-of-Care MDx Development

Resilience Health Curating COVID-19 Molecular Tests for Employers, Public Benefit

With New NIH Funding, PathogenDx Pivots From Cannabis Screening to Clinical Diagnostics

Biodesix Turns to Digital PCR to Maintain Round-The-Clock COVID Testing

Many Initiatives Turning to RT-LAMP as Alternative to PCR for Rapid COVID-19 Screening Assays

Breaking News

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

Sponsorships